FDA drug candidacy acceptance criteria and steps: problems and way forward
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | Ezzat, Shahira M | |
dc.contributor.author | Helmy, Mahitab | |
dc.contributor.author | Walag, Angelo Mark P | |
dc.contributor.author | Mtewa, Andrew | |
dc.date.accessioned | 2020-01-23T15:13:27Z | |
dc.date.available | 2020-01-23T15:13:27Z | |
dc.date.issued | 2019-08 | |
dc.identifier.doi | https://doi.org/ | |
dc.identifier.other | https://doi.org/ | |
dc.identifier.uri | https://t.ly/dgr3M | |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartofseries | In book: Phytochemicals as Lead Compounds for New Drug Discovery, Publisher: Elsevier,;pp.39-63 | |
dc.subject | university of | en_US |
dc.title | FDA drug candidacy acceptance criteria and steps: problems and way forward | en_US |
dc.type | Book chapter | en_US |